PCSK9 inhibitors and their use in advanced heart failure and heart transplant recipients

Abstract

The use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has garnered widespread attention in the medical community over the past ten years. A number of landmark trials have demonstrated the efficacy of PCSK9 inhibitors in lowering low-density lipoprotein (LDL) levels dramatically when added to background statin therapy. Importantly, their use has led to a significant reduction in adverse events in patients at risk and with established cardiovascular diseases. Published evidence is sparse in the heart failure (HF) population, especially in those with Stage D disease. While the use of PCSK9 inhibitors has not been reported in patients with durable mechanical circulatory support devices, limited data exist in heart transplant recipients. Management of dyslipidemia is critically important in post-heart transplant population as it contributes to the development of cardiac allograft vasculopathy (CAV). However, most 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) interfere with the metabolism of commonly used immunosuppressant agents, such as tacrolimus. Case studies in post-heart transplant patients demonstrated significant LDL reduction with PCSK9 inhibitor use, without significant drug-drug interactions or adverse events. Two trials are currently underway examining their efficacy in reducing CAV progression. This paper aims to review the available clinical evidence for PCSK9 inhibitor use in HF patients, with specific focus on the advanced heart failure group.

Keywords

PCSK9 inhibitors / left ventricular assist device / heart transplant / heart failure

References

[1] Rosenson RS,Fazio S.The evolving future of PCSK9 Inhibitors..J Am Coll Cardiol2018;72:314-29

[2] Ference BA,Graham I.Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel..Eur Heart J2017;38:2459-72 PMCID:PMC5837225

[3] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins..Lancet2005;366:1267-78

[4] Grundy SM,Bailey AL.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology/American heart association task force on clinical practice guidelines..J Am Coll Cardiol2019;73:e285-350

[5] Authors/Task Force Members, ESC committee for practice guidelines (CPG), ESC national cardiac societies2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk..Atherosclerosis2019;290:140-205

[6] Roth EM.PCSK9 Inhibitors: mechanism of action, efficacy, and safety..Rev Cardiovasc Med2018;19:S31-46

[7] Goldstein JL.The LDL receptor..Arterioscler Thromb Vasc Biol2009;29:431-8 PMCID:PMC2740366

[8] Ding Z,Liu S.PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy..Cardiovasc Res2018;114:1738-51

[9] Ding Z,Goel A,Mehta JL.PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1..Cardiovasc Res2020;116:908-15

[10] Ding Z,Wang X.Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis..Antioxid Redox Signal2016;25:997-1008

[11] Ding Z,Wang X.Cross-talk between LOX-1 and PCSK9 in vascular tissues..Cardiovasc Res2015;107:556-67

[12] Ding Z,Wang X.Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta..Antioxid Redox Signal2015;22:760-71 PMCID:PMC4361218

[13] Ding Z,Wang X.PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages..Cardiovasc Res2018;114:1145-53

[14] Cadenas S.ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection..Free Radic Biol Med2018;117:76-89

[15] von Harsdorf R,Dietz R.Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis..Circulation1999;99:2934-41

[16] Zhao ZQ,Wang NP.Progressively developed myocardial apoptotic cell death during late phase of reperfusion..Apoptosis2001;6:279-90

[17] Palee S,Maneechote C.PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid-lowering effects..J Cell Mol Med2019;23:7310-9 PMCID:PMC6815840

[18] Sabatine MS,Wiviott SD.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events..N Engl J Med2015;372:1500-9

[19] Schwartz GG,Szarek M.Alirocumab and cardiovascular outcomes after acute coronary syndrome..N Engl J Med2018;379:2097-107

[20] Murphy SA,Gaciong ZA.Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial..JAMA Cardiol2019;4:613-9 PMCID:PMC6537798

[21] Giugliano RP,Park J.Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial..Lancet2017;390:1962-71

[22] Gürgöze MT,Schreuder MM,Boersma E.Adverse events associated with PCSK9 inhibitors: a real-world experience..Clin Pharmacol Ther2019;105:496-504 PMCID:PMC6704355

[23] Kosmas CE,Sourlas A.Inclisiran: a new promising agent in the management of hypercholesterolemia..Diseases2018;6:63 PMCID:PMC6163360

[24] Momtazi-Borojeni AA,Badiee A,Sahebkar A.Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis..BMC Med2019;17:223 PMCID:PMC6902459

[25] Wu D,Pan Y.Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid β-Oxidation..J Am Heart Assoc2020;9:e014358 PMCID:PMC6988173

[26] Cholesterol treatment trialists’ (CTT) collaborationEfficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials..Lancet2010;376:1670-81 PMCID:PMC2988224

[27] Boekholdt SM,Mora S.Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials..J Am Coll Cardiol2014;64:485-94 PMCID:PMC4443441

[28] Yancy CW,Bozkurt B.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America..J Am Coll Cardiol2017;70:776-803

[29] Ponikowski P,Anker SD.Developed with the special contribution of the heart failure association (HFA) of the ESC..Eur J Heart Fail2016;18:891-975

[30] Florkowski CM,George PM.Rosuvastatin in older patients with systolic heart failure..N Engl J Med2008;358:1301

[31] Gissi-hf investigators.Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial..Lancet2008;372:1231-9

[32] Bayes-Genis A,Zannad F.The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis..J Am Coll Cardiol2017;70:2128-36

[33] Tang Z,Peng J.PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages..Int J Mol Med2012;30:931-8

[34] Stulak JM,Haglund N.Adverse events in contemporary continuous-flow left ventricular assist devices: A multi-institutional comparison shows significant differences..J Thorac Cardiovasc Surg2016;151:177-89

[35] Goldstein DJ,Xie R.Third annual report from the ISHLT mechanically assisted circulatory support registry: a comparison of centrifugal and axial continuous-flow left ventricular assist devices..J Heart Lung Transplant2019;38:352-63

[36] Mehra MR,Naka Y.A fully magnetically levitated left ventricular assist device-final report..N Engl J Med2019;380:1618-27

[37] Vieira JL,Claggett BL.The impact of statin therapy on neurological events following left ventricular assist system implantation in advanced heart failure..J Heart Lung Transplant2020;39:582-92

[38] Costanzo MR,Starling R.The international society of heart and lung transplantation guidelines for the care of heart transplant recipients..J Heart Lung Transplant2010;29:914-56

[39] Khush KK,Chambers DC.The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult heart transplantation report-2018; focus theme: multiorgan transplantation..J Heart Lung Transplant2018;37:1155-68

[40] Lu WH,Fishbein GA.Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts..J Heart Lung Transplant2011;30:1044-50

[41] Rahmani M,Granville DJ.Allograft vasculopathy versus atherosclerosis..Circ Res2006;99:801-15

[42] Lee F,Chih S.Cardiac allograft vasculopathy: insights on pathogenesis and therapy..Clin Transplant2020;34:e13794

[43] Lund LH,Dipchand AI.The registry of the international society for heart and lung transplantation: thirty-third adult heart transplantation report-2016; focus theme: primary diagnostic indications for transplant..J Heart Lung Transplant2016;35:1158-69

[44] Kühl M,Jozwiak J.Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation..PLoS One2019;14:e0210373 PMCID:PMC6335020

[45] Moayedi Y,Knowles JW.Safety and efficacy of PCSK9 inhibitors after heart transplantation..Can J Cardiol2019;35:104.e1-3

[46] Toth PP,Genest J.Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies..Circulation2017;135:1819-31

[47] Catapano AL.The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway..Atherosclerosis2013;228:18-28

[48] Simha V,Shah P.Sirolimus therapy is associated with elevation in circulating PCSK9 levels in cardiac transplant patients..J Cardiovasc Transl Res2017;10:9-15 PMCID:PMC5325778

[49] Warden BA,Minnier J,Fazio S.Use of PCSK9 inhibitors in solid organ transplantation recipients..JACC: Case Reports2020;2:396-9

[50] Sandesara PB,Hirsh B,Cole RT.PCSK9 inhibition in patients with heart transplantation: a case series..J Clin Lipidol2019;13:721-4

[51] Groba-Marco MDV,Barge-Caballero G,Couto-Mallón D.Treatment of Hypercholesterolemia With PCSK9 inhibitors in heart transplant recipients. First experience in spain..Rev Esp Cardiol (Engl Ed)2019;72:1084-6

[52] Jennings DL,Farr M.PCSK9 inhibitor use in heart transplant recipients: a case series and review of the literature..Transplantation2020;104:e38-9

[53] Walley KR,Russell JA.PCSK9 is a critical regulator of the innate immune response and septic shock outcome..Sci Transl Med2014;6:258ra143 PMCID:PMC4342147

[54] Bjerre KP,Poulsen SH.Micro- and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular biomarkers in heart transplant recipients-An exploratory study..Clin Transplant2020;e14133

[55] Broch K,Karason K.Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: design of the randomized controlled EVOLVD trial..Clin Transplant2020;34:e13984

[56] Fearon W. National Institute of Health, US National Library of Medicine, clinicaltrials.gov. PCSK9 Inhibition After Heart Transplantation. Available from: https://clinicaltrials.gov/ct2/show/NCT03537742. [Last accessed on 9 Dec 2020]

[57] Di Nora C,Livi U.Safety and efficacy of PCSK9 inhibitor treatment in heart transplant patients..Transplantation2019;103:e58